Welcome to our dedicated page for Hims & Hers Health news (Ticker: HIMS), a resource for investors and traders seeking the latest updates and insights on Hims & Hers Health stock.
Hims & Hers Health, Inc. (HIMS) is a cutting-edge telehealth company, headquartered in San Francisco, California, that revolutionizes the way people access healthcare. Founded in 2013, the company provides a multi-specialty platform connecting consumers to licensed healthcare professionals, offering a seamless path to high-quality medical care for various conditions.
Hims & Hers Health, Inc. specializes in a broad range of wellness products and services. Their portfolio includes treatments for hair loss, sexual wellness products, skincare lines, and oral care solutions. The company also diversifies its offerings through an exclusive range of men's fashion items including sweaters, jackets, corduroy, sport coats, wool overcoats, leather boots, flannel shirts, caps, and candles. All products are conveniently available for purchase through their online platform.
The telehealth services provided by Hims & Hers are comprehensive, covering mental health, sexual health, dermatology, primary care, and more. This robust platform ensures consumers receive professional medical consultations from the comfort of their homes.
Hims & Hers Health, Inc. continues to innovate and expand its services to meet the evolving needs of its customers. Recent achievements include advancements in their telehealth technology, expanding partnerships with renowned medical professionals, and enhancing their product lines. The company is financially sound and continues to grow, reflecting positive market performance and consumer trust.
For the latest updates, financial reports, and company news, Hims & Hers Health remains a significant player in both the wellness product market and the telehealth industry.
Hims & Hers Health reported a 79% year-over-year revenue increase for Q3 2021, totaling $74.2 million, surpassing guidance. The company achieved 551,000 member subscriptions, a 95% increase from the previous year. Despite strong growth, the net loss widened to $(15.9) million, compared to $(5.9) million in Q3 2020, and Adjusted EBITDA remained negative at $(9.8) million. The company expects revenue for Q4 2021 between $76 million and $78 million and a full-year revenue forecast of $263 million to $265 million.
Hims & Hers Health, Inc. (NYSE:HIMS) announced participation in the Credit Suisse 30th Annual Healthcare Conference on November 11, 2021. CEO Andrew Dudum and Chief Medical Officer Patrick Carroll will hold one-on-one meetings and a live webcast of Dudum's fireside chat is scheduled for 4:20 PM ET. The webcast will be accessible on Hims & Hers investor relations website and archived for 90 days. The company, founded in November 2017, offers a multi-specialty telehealth platform providing access to healthcare for various conditions across the U.S.
Hims & Hers (NYSE: HIMS) and Walgreens (NASDAQ: WBA) have announced a collaboration to enhance access to health and wellness solutions. Hims & Hers products, including supplements and sexual health offerings, will be available at over 7,000 Walgreens locations and on walgreens.com starting early November. This partnership aims to destigmatize health topics and support Hims & Hers' goal of mass market accessibility, providing trusted health products to consumers in the U.S.
Hims & Hers has launched the Climax Delay Wipes, a non-prescription treatment aimed at addressing premature ejaculation, which affects nearly 1 in 4 men. These single-use benzocaine wipes are designed to help men maintain erections and gain better control over their climax. This addition complements existing products like Climax Delay Spray and various prescription options available through telehealth consultations. CEO Andrew Dudum emphasized the company's mission to enhance personalized healthcare access, providing a range of solutions for sexual health.
Hims & Hers Health, a telehealth platform, will release its fiscal third quarter financial results on November 10, 2021, after the market closes. A conference call is scheduled for 5:00 p.m. E.T. The company connects consumers to healthcare professionals for a variety of medical concerns, including primary care and mental health. Hims & Hers operates across all 50 states and Washington, D.C., providing accessible healthcare solutions. Investors and media are invited to access the live call or listen to a replay online.
Regis Corporation (NYSE:RGS) announces John Davi as the new Chief Technology Officer, aiming to enhance its Opensalon ecosystem. With over 20 years in technology, Davi has previously worked with BriteCore and MINDBODY, and has experience in artificial intelligence and media solutions. His expertise is expected to drive technology development and improve franchisee support. Regis operates the world's largest franchise network of hair salons, with 5,917 locations globally as of June 30, 2021.
Hims & Hers Health, Inc. (NYSE: HIMS) has partnered with The Vitamin Shoppe to expand the availability of its haircare products. Starting now, customers can purchase Hims & Hers products both online and in over 280 Vitamin Shoppe locations. This partnership will initially focus on haircare solutions, including popular items such as Minoxidil treatments and biotin gummies, with plans for future expansion into other product lines. The collaboration aims to enhance consumer access to personalized health and wellness solutions.
Hims & Hers Health has launched new skincare offerings, including the Hims Overnight Anti-Aging Duo and Hers Clear Skin System. The Overnight Anti-Aging Duo features a customizable prescription Anti-Aging Cream and a nonprescription Goodnight Wrinkle Cream targeted at wrinkles and sun damage. The Hers Clear Skin System offers a customizable prescription acne cream alongside hydrating cleanser and moisturizer. Both products emphasize individual customization through consultations with healthcare providers, enhancing the company's telehealth service model.
Hims & Hers Health has launched a new D-Mannose dietary supplement, aimed at improving urinary tract health for women. Available on ForHers.com, this product comes in single-serve packets that combine D-Mannose, vitamins, and electrolytes. The initiative addresses a significant health need, as 30-40% of women experiencing a urinary tract infection will have another within six months. This highlights the company's commitment to providing holistic health solutions that are accessible and user-friendly.
Hims & Hers announced a strategic partnership with REVOLVE, allowing a diverse range of health and wellness products to be sold on REVOLVE.com. This collaboration targets Millennial and Generation Z consumers by offering affordable skincare, hair care, sleep supplements, and sexual health products. Both companies aim to enhance their brands' appeal in the consumer health and fashion sectors. This partnership follows Hims & Hers' role as the exclusive wellness partner at REVOLVE's New York Fashion Week events, further solidifying their joint brand outreach.
FAQ
What is the current stock price of Hims & Hers Health (HIMS)?
What is the market cap of Hims & Hers Health (HIMS)?
What does Hims & Hers Health, Inc. do?
Where is Hims & Hers Health, Inc. based?
When was Hims & Hers Health, Inc. founded?
What types of products does Hims & Hers offer?
What medical services are available through Hims & Hers?
How can I purchase products from Hims & Hers?
How is Hims & Hers Health, Inc. performing financially?
What recent achievements has Hims & Hers Health, Inc. made?
Does Hims & Hers collaborate with healthcare professionals?